ツロブテロール経皮吸収型製剤の設計と気管支喘息の時間治療

概要

論文の詳細を見る
It is well known that vulnerable period exists in the manifestation of asthma with maximum incidence of asthma attacks in early morning at around 4 a.m. due to morning dip in circadian rhythm. Oral dosage forms of β 2-adrenergic agonists have been widely used to treat asthma patients. But they cannot cover the time of morning dip, and side effects such as palpitation and tremor caused by of excessive serum levels around Tmax limit their usefulness. Chronotherapy for asthma treatment based on circadian rhythm was considered that it would be more efficient and had a lower frequency of side effects. Accordingly we developed a novel transdermal drug delivery system of the β 2-agonist tulobuterol adapted to the circadian rhythm. The system is designed to administer the appropriate dose of drug at the optimal time by transdermal delivery system with Crystal Reservoir System. The superiority of the transdermal formulation of tulobuterol over the current therapy using oral formulations of β 2-stimulants was indicated by its excellent pharmacokinetic profile, and confirmed by the results of clinical trials. This formulation is the worldwide first transdermal chrono-delivery system for asthma treatment, and is expected to provide more effective and safe treatment of asthma and related diseases not only in adults, but also especially in children.
日本膜学会の論文
2003-11-01